Phase 1
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type

Drug Details

IW001 is a therapeutic designed to treat anti-Col (V)-mediated autoimmune diseases via oral tolerance. 

Study Purpose

This is an open label, Phase One, multicenter study, designed to evaluate the safety, tolerability, to explore the biologic effects, and to explore the clinical effects of the following doses of IW001: 0.1mg/day, 0.5 mg/day, and 1.0 mg/day, when administered once a day orally for 24 weeks in patients with IPF.

This drug has no clinical trials actively recruiting patients at this time.


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >